The top amount of exits for fund were in 2017. The fund is constantly included in less than 2 deals per year. The usual things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2015.
Among the most popular portfolio startups of the fund, we may highlight Ovid Therapeutics. We can highlight the next thriving fund investment areas, such as Health Care, Biotechnology. Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund.
The usual cause for the fund is to invest in rounds with 8 partakers. The meaningful sponsors for the fund in investment in the same round are Tekla Capital Management, Sphera Funds Management, Sanofi-Genzyme BioVentures.
| Fund Name | Location |
| Alfa Ventures | Delhi, Delhi, India |
| Enlight Media | Beijing, Beijing, China |
| Equity Resources Group | Cambridge, Massachusetts, United States |
| Harbin Yungu Venture Capital Enterprise | China, Harbin, Heilongjiang |
| Huihua Investment | China, Fenghua, Zhejiang |
| Kerun Chuangtou | China, Shanghai |
| Livzon Pharmaceutical Group | China, Guangdong, Zhuhai |
| NXT Capital | Chicago, Illinois, United States |
| Qicheng Chuang Tou | China, Dongguan, Hebei |
| Qixi Capital | - |
| Quintus Vermoegensverwaltung GmbH | - |
| Starboard Value | New York, New York, United States |
| Startup:Education | New Jersey, Newark, United States |
| Stokke Industri | - |
| UniCredit EVO | Italy, Lombardia, Milano |
| Velos Partners | California, Los Angeles, United States |
| Viscogliosi Brothers | New York, New York, United States |
| Westcott LLC | Dallas, Texas, United States |
| ZJKF Capital Management | China, Hangzhou, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Ovid Therapeutics | $75M | 11 Aug 2015 | New York, New York, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Ovid Therapeutics | $75M | 11 Aug 2015 | New York, New York, United States |
